Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the commercialization of pharmaceutical products for dermatological conditions, with a focus on photodynamic therapy (PDT). Founded in March 2015 as a wholly-owned subsidiary of Germany's Biofrontera AG, it became an independent public company on November 2, 2021, and is listed on NASDAQ under the ticker BFRI. Its headquarters are located in Woburn, Massachusetts. As of December 31, 2023, the company had 85 employees, growing to 94 by July 2026. For the fiscal year 2025, Biofrontera Inc. reported annual revenue of $41.71 million, with Q1 2026 revenues at $10.1 million.

The company's primary products include the FDA-approved flagship drug Ameluz® (aminolevulinic acid hydrochloride gel, 10%) and the BF-RhodoLED® lamp series. Ameluz® PDT is indicated for the treatment of actinic keratoses (AK), which are pre-cancerous skin lesions. Biofrontera Inc. commercializes these products directly to dermatology offices and groups in the United States. The company also conducts research and development activities to support PDT growth and explore new indications. In October 2025, Biofrontera Inc. acquired full U.S. rights to Ameluz® and RhodoLED®, including the New Drug Application (NDA) and associated patents, from its former parent Biofrontera AG.

Biofrontera Inc. appears to be an active two-way litigant in patent disputes, based on its equal number of plaintiff and defendant cases. The company has one case as a plaintiff (Biofrontera Pharma GMBH et al. v. Sun Pharmaceutical Industries Inc. at the Patent Trial and Appeal Board, filed 2024-08-21) and one case as a defendant (Sun Pharmaceutical Industries, Inc. v. Biofrontera Inc. in the U.S. District Court for the District of Massachusetts, filed 2024-06-25). These cases suggest an active role in both asserting and defending its intellectual property related to its dermatological products.

A notable aspect of its litigation context is the ongoing dispute with Sun Pharmaceutical Industries Inc., involving both a district court case where Biofrontera Inc. is a defendant and a PTAB proceeding where it is a plaintiff. This indicates a direct patent conflict over the company's core technology or products. The acquisition of full U.S. patent rights for Ameluz® and RhodoLED® in October 2025 positions Biofrontera Inc. with direct control over its intellectual property in the U.S. market, which is likely reflected in its litigation activities.